Ultravision is a revolutionary new system that clears surgical smoke from the visual field
and prevents its release into the operating theatre during laparoscopic surgery.
It achieves this effortlessly and unobtrusively by accelerating
the natural sedimentation of the smoke particles.
Surgical smoke is a significant issue during laparoscopic surgery:
Current vacuum-based solutions used in open surgery have proved to be largely ineffective in meeting the needs of the surgical team:
For these reasons the uptake of vacuum systems in laparoscopic surgery has been poor.
Ultravision revolutionises the way in which surgical smoke is handled and transforms the operating theatre environment during laparoscopic surgery.
*Ultravision performance and safety has been demonstrated in bench studies, preclinical and clinical testing including a clinical study on 30 patients undergoing laparoscopic cholecystectomy
The Ultravision technology is based upon “electrostatic precipitation”, an existing technology that has proved to be a highly effective means of removing airborne particulates. The technology shares the same principle as monopolar diathermy in that it requires a patient return electrode to function. Although the technology has applications in many minimal access surgery (MAS) procedures, Asalus has initially focused on the use of Ultravision in laparoscopic surgery.
The Ultravision technology involves the following steps:
This is achieved using a conventional patient return electrode, which can be shared with an electrosurgical generator by using the Patient Return Adaptor.
Delivering a voltage to the abdominal cavity
The Ultravision generator and Ionwand deliver a low energy DC current to the abdominal cavity. The power is 400-1000x less than electrosurgical instruments.
Creating a flow of negative gas ions
The DC energy source creates negative gas ions in the abdominal cavity that flow towards patient tissue
The gas ions collide with the smoke particles as they are created. The smoke particles migrate to patient tissue where they are deposited.
The negative charge returns to the generator via the patient return adaptor and the gas ions are neutralised.
The Ultravision system comprises reusable and
Asalus was established in 2009 to commercialise the
inventions arising from the Welsh Institute for
Minimal Access Therapy (WIMAT).
Based in Cardiff, WIMAT is the leading UK centre for
training of laparoscopic and other surgical disciplines.
Our vision is to become a world leader in the development of new devices for advanced minimal access surgery
We work with leading surgeons to identify and resolve issues commonly experienced when performing complex surgical procedures. Solving these issues will make these techniques easier and faster for the surgical team, safer for the patient, and more cost-effective for the healthcare provider.
Routine access to highly experienced key opinion leaders and new trainees places WIMAT in a privileged position to receive feedback on the demands of modern surgical techniques from highly experienced practitioners and those new to the field. Asalus works with WIMAT and its network to identify issues with these procedures and potential solutions to them. Asalus then rapidly prototypes medical devices and through usability testing assesses whether or not the devices are capable of addressing these issues.
Projects that successfully pass this decision point then enter full development. The company has strong relationships with a broad network of product development partners that allow it to take forward a wide range of mechanical and electrical product concepts. Asalus is focusing initially on the commercialisation of Ultravision but is constantly seeking and evaluating new product development opportunities. We welcome the opportunity to discuss such opportunities with commercial, academic and medical institutions.
DAVID FREDERICK (Non-executive Chairman)
Previously VP Sales and
Marketing EMEA, Covidien
Managing Director, Healthcare 21 Limited
DOMINIC GRIFFITHS (Managing Director)
Ex-strategy consultant Gemini Consulting,
Director of Business Development
Phoqus PLC, Investment Manager,
Fusion IP PLC
Expertise in early stage company creation
and founder director of Asalus
NEIL WARREN (Chief Scientific Officer, Director)
Head of WIMAT and internationally
recognised trainer in minimal
Extensive medical and industry network
DAVID MARSH (Non-exec Director)
Founding Director of Elemental
Healthcare (UK distributor)
Ex-Managing Director of
Gyrus’ Direct Operations
PETER GRANT (Non-exec Director)
Operations Director of Fusion IP PLC,
Co-Founder of Celsis
PETER BANNISTER (Head of Operations)
Extensive technical and management
experience in biomedical, aerospace,
automotive and computer engineering
Previously Chief Scientific Officer at
Eykona Technologies Limited
Asalus will be exhibiting its revolutionary Ultravision laparoscopic surgical smoke handling system at the 2013 Medica event. Medica is one of the largest tradeshows for medical companies in the world and is taking place in Dusseldorf (Germany) from 20-23 November. The Company is being supported by the Welsh Government and will be exhibiting in Hall 16, Stand F30. In addition it will also be showcasing the technology in the Association of British Healthcare Industries (ABHI) virtual Operating Theatre display and presenting to potential Commercial Officers and buyers at 11:45 on Friday 22 November at the UK Pavilion stand in Hall 16. The Company is seeking distributors for Ultravision, pending CE mark approval in 2014.
Asalus will be exhibiting at the 2013 Association of Laparoscopic Surgeons of Great Britain and Ireland (ALSGBI) and Association of Laparoscopic Theatre Staff (ALTS) meeting, taking place at the Royal College of Surgeons on 14 and 15 November, 2013. The Company will be presenting its revolutionary Ultravision laparoscopic surgical smoke handling system to future end-users at a conference for the first time, in anticipation of its European launch in 2014.
Asalus UK Office Suite 18, Cardiff Medicentre, Heath Park,
Cardiff CF14 4UJ, United Kingdom.
+44 (0) 29 2068 2106